A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin Adolescents and Children With Chronic HCV-Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 05 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Nov 2017 Planned number of patients changed from 220 to 222.
- 28 Nov 2017 Planned End Date changed from 1 Jul 2018 to 1 Aug 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History